Envestnet Asset Management
LXRX icon

Envestnet Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Envestnet Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-83,407
Closed -$166K – 3145
2020
Q2 		$166K Buy
+83,407
New +$163K ﹤0.01% 2910
2017
Q4 		– Sell
-2,114
Closed -$26K – 2985
2017
Q3 		$26K Buy
2,114
+110
+5% +$1.62K ﹤0.01% 2447
2017
Q2 		$32K Buy
2,004
+111
+6% +$1.72K ﹤0.01% 2481
2017
Q1 		$27K Buy
1,893
+23
+1% +$341 ﹤0.01% 2604
2016
Q4 		$25K Buy
1,870
+320
+21% +$5.13K ﹤0.01% 2616
2016
Q3 		$28K Sell
1,550
-95
-6% -$1.53K ﹤0.01% 2750
2016
Q2 		$24K Sell
1,645
-345
-17% -$4.68K ﹤0.01% 2938
2016
Q1 		$24K Buy
+1,990
New +$20.9K ﹤0.01% 2932

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Envestnet Asset Management's LXRX Position: Q3 2020 in Review

Envestnet Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2020, closing a stake of 83,407 shares — an estimated $166K sold.

Envestnet Asset Management first reported a position in LXRX in Q1 2016 and held it in 8 quarters. The position peaked at $166K in Q2 2020. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

  • Envestnet Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Envestnet Asset Management sold 83,407 Lexicon Pharmaceuticals shares in Q3 2020, an estimated $166K.
  • Envestnet Asset Management first reported a position in Lexicon Pharmaceuticals in Q1 2016 and held it in 8 quarters.
  • Envestnet Asset Management's Lexicon Pharmaceuticals position peaked at $166K in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on Envestnet Asset Management's 13F filing for Q3 2020, filed 9 Oct 2020.